11 results about "Serum uric acid" patented technology

The invention discloses a xanthine oxidase inhibitory peptide with uric acid reducing activity and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is obtained by conducting enzymolysis, separation and purification on processing byproducts such as litopenaeus vannamei heads and shells with xanthine oxidase inhibitory activity. The xanthine oxidase inhibitory peptide is screened by using a molecular docking technology, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Pro-Val-Pro-Pro-Pro. The xanthine oxidase inhibitory peptide has an XOD (X-Oxidase) half inhibitory concentration of 3.181 + / -0.1786 mM. The invention further proves that the xanthine oxidase inhibitory peptide has a certain improvement effect on hyperuricemia mice, and the xanthine oxidase inhibitory peptide mainly has the effects of reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and liver of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and the xanthine oxidase inhibitory peptide has a certain improvement effect on the hyperuricemia mice through Toxinpred prediction. The xanthine oxidase inhibitory peptide uric acid reducing peptide is free of toxic and side effects and has a wide market application prospect.

The invention belongs to the technical field of medical diagnosis, and particularly relates to a visual column diagram construction method for identifying and diagnosing suppurative and tuberculous lumbar major muscle abscesses and interactive application. According to the invention, it is found that six indexes including serum uric acid (UA), thrombin time (TT), neutrophil absolute value (NEUT #), age (Age), fever (Fever) and erythrocyte sedimentation rate (ESR) are related to the type of the lumbar major muscle abscess, and a visual column diagram construction method for identifying and diagnosing suppurative and tuberculous lumbar major muscle abscess and interactive application are invented. And a first visual and quantifiable column diagram (Nomogram) prediction model for differential diagnosis of lumbar major muscle abscess is provided for the field. The technical problem that an abstract mathematical prediction model is converted into a visual graphic diagnosis tool which is intuitive in form and convenient to operate is solved, so that the visual graphic diagnosis tool can be separated from dependence on specific computing equipment, and clinical medical staff can quickly and accurately apply the visual graphic diagnosis tool on a diagnosis and treatment site conveniently.

Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.

This invention discloses urinary metabolic biomarkers for hyperuricemia and their applications, relating to the field of metabolomics technology. It aims to overcome the shortcomings of traditional serum uric acid detection, such as susceptibility to interference, insufficient early warning capabilities, and a lack of sensitive, specific, and non-invasive biomarkers. The urinary metabolic biomarker is at least one of L-kynurenine, indole, and betaine, which can be used to prepare reagents or kits. The assessment system includes a sample analysis unit and a risk assessment model. This invention enables non-invasive and convenient detection of hyperuricemia, accurately captures early metabolic abnormalities, provides reliable risk stratification, and supports clinical auxiliary diagnosis and pathogenesis research.

The invention provides a pharmaceutical composition for preventing, treating or relieving uric acid metabolic disorder and application, the pharmaceutical composition comprises a xanthine oxidase inhibitor and a URAT1 inhibitor, and the xanthine oxidase inhibitor is selected from teguxostat or febuxostat; the URAT1 inhibitor is selected from the group consisting of dotenod, Velnod, Lesinurad, Ruzinurad, SAP-001, ABP-671, SHR4640 and the like. The pharmaceutical composition provided by the invention can effectively reduce the concentration of uric acid in serum of a patient with hyperuricemia, so that the hyperuricemia is effectively prevented, treated or relieved. Compared with a single drug and the sum thereof, the combined drug composition can effectively inhibit serum uric acid, serum creatinine and urea nitrogen.

The invention discloses application of a soybean extracting solution in preparation of a uric acid reducing product, and belongs to the technical field of plant extract application. A preparation method of the soybean extracting solution comprises the following steps that soybeans with the water content being 55% or above are flatly laid on a conveying belt, the soybeans are conveyed into extraction equipment disclosed by the patent ZL 201711472613.5 through the conveying belt, the soybeans sequentially pass through 11 plasma effect generator cracking reaction kettles, the reaction time of each plasma effect generator cracking reaction kettle is 40-60 seconds, and the soybean extracting solution is obtained. The microwave power of the cracking reaction kettles of the first 10 plasma effect generators is 1-6 KW, and the microwave power of the cracking reaction kettles of the last plasma effect generator is 1-3 KW. The soybean extracting solution provided by the invention reduces the generation of uric acid by inhibiting the activity of xanthine oxidase, regulates and controls a TNF signal channel to relieve inflammatory damage, and can effectively reduce the serum uric acid content of a hyperuricemia individual. The extracting solution and a pharmaceutically acceptable carrier can be prepared into a medicine, and a safe and effective new way is provided for prevention and treatment of hyperuricemia.

The invention discloses a brassica rapa flavonoid extract with uric acid reducing activity as well as a preparation method and application of the brassica rapa flavonoid extract. According to the preparation method disclosed by the invention, process parameters are optimized by combining an ultrasonic-assisted extraction method with response surface analysis, the high-content and high-purity brassica rapa flavonoid extract is prepared, quercetin-3-glucuronide is determined as a main component of the brassica rapa flavonoid extract, and the remarkable treatment effect of the brassica rapa flavonoid extract on hyperuricemia is verified through in-vitro experiments and animal experiments; the brassica rapa flavonoid extract not only can effectively inhibit the activity of xanthine oxidase (XOD) and reduce the level of serum uric acid, but also can relieve inflammatory response of the kidney and improve pathological injury of the kidney, meanwhile, the preparation process is efficient and environmentally friendly, and a new direction is provided for development of safe and effective natural drugs.

The invention discloses a functional hydrogen water formula capable of promoting uric acid excretion of gout, the functional hydrogen water formula comprises the following components: hydrogen, purified water, sodium bicarbonate, a magnesium ion compound and a vitamin C derivative, the dissolution concentration of the hydrogen in water is 0.8-2.0 mg / L, the addition amount of the sodium bicarbonate is 0.5-3.0 g / L, the concentration of the magnesium ion compound is 10-50 mg / L in terms of magnesium element, the concentration of the vitamin C derivative is 10-50 mg / L in terms of magnesium element, and the concentration of the vitamin C derivative is 0.5-1.0 mg / L. The addition amount of the vitamin C derivative is 0.1-1.0 g / L. The functional hydrogen water can accurately promote uric acid excretion, the serum uric acid (SUA) is reduced by 43.9% (216.3 + / -20.7 [mu] mol / L) compared with a model group and the urinary uric acid (UUA) is increased by 90.7% (238.9 + / -19.8 [mu] mol / 24h) in 24 hours after the functional hydrogen water intervenes in a hyperuricemia rat for 21 days, and the functional hydrogen water is superior to common hydrogen water and can be comparable to benzbromarone. The mechanism is as follows: sodium bicarbonate adjusts the pH value to 7.5-8.5 to help to dissolve urate, magnesium + hydrogen down-regulates URAT1 (reduced by 46.5%), up-regulates GLUT9 (increased by 93.1%) to reduce uric acid reabsorption, and also improves the activity of liver uricase (increased by 61.1%) to assist decomposition, so that a multi-channel excretion promoting system is formed.

The invention belongs to the technical field of biological medicines, and discloses application of a deep-sea butyrolactone compound in preparation of a product for preventing and / or treating hyperuricemia and / or uric acid nephropathy. The butyrolactone compound disclosed by the invention is specifically 5-acetyl-3-hydroxy-4-(4-hydroxyphenyl)-5-[4-methyl-3-(3-methylbutyl-2-ene-1-yl) benzyl] furan-2 (5H)-ketone, and the structural formula of the butyrolactone compound is shown in the description. It is proved for the first time that the butyrolactone compound has the capacity of remarkably improving hyperuricemia and uric acid nephropathy, and the blood uric acid level, the serum creatinine level and the blood urea nitrogen level of hyperuricemia mice induced by oteracil potassium and hypoxanthine and uricase knockout mice are remarkably improved; the compound can be applied to preparation of products for preventing and / or treating the hyperuricemia and / or the uric acid nephropathy, a new product is provided for prevention and treatment of the hyperuricemia and the uric acid nephropathy, and therefore the compound has a wide application prospect.

The invention discloses a composition for relieving hyperuricemia as well as a preparation method and application thereof. The method comprises the following steps: firstly, extracting active ingredients from a traditional Chinese medicine mixture consisting of chrysanthemum, selfheal, sophora flower, corn stigma and honeysuckle; and then sequentially loading by using a PSBMA-glycyrrhetinic acid compound and a diphenylalanine dipeptide-beta-cyclodextrin compound, so as to obtain the composition. The composition is loaded with active ingredients through a cage type interpenetrating structure, has temperature / pH dual response release characteristics, is released in an intestinal tract in a targeted manner, and can efficiently inhibit xanthine oxidase, remarkably reduce the levels of serum uric acid, urea nitrogen and creatinine of a hyperuricemia mouse, improve the renal function and play an anti-inflammatory role. The method can be used for preparing medicines such as granules and tablets, and has a good application prospect in products for relieving hyperuricemia.